Cytokinetics (CYTK) Tops Q4 EPS by 43c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Cantor Fitzgerald Remains Bullish on Cytokinetics (CYTK)
February 17, 2017 7:50 AM ESTCantor Fitzgerald reiterated an Overweight rating and $21.00 price target on Cytokinetics (NASDAQ: CYTK). 4Q16 fully diluted EPS was $0.16, which was better than ($0.43) forecasts due to the inclusion of a $26 mln payment from Amgen for omecamtiv mecarbil.
Analyst Mara Goldstein commented, "We rate CYTK Overweight... More
FBR Capital Reiterates Outperform on Cytokinetics (CYTK) Following 4Q
February 17, 2017 7:17 AM ESTFBR Capital reiterated an Outperform rating and $24.00 price target on Cytokinetics (NASDAQ: CYTK) following the company's 4Q earnings report.
Analyst Vernon Bernardino commented, "On February 16, CYTK announced 4Q16 results dominated by the achievement of significant milestones in its cardiac muscle-directed clinical program... More
Piper Jaffray Reiterates Overweight Rating and $15 PT on Cytokinetics (CYTK) Following 4Q16 Results
February 17, 2017 6:05 AM ESTPiper Jaffray analyst Charles Duncan reiterates Overweight rating and $15 price target on Cytokinetics Inc. (NASDAQ: CYTK), suggesting the companys cash position provides strong 12 month upside potential, as 2016 fourth quarter results include $33 million in revenues and $156 million in year-end cash.
Duncan comments, "On Thursday AMC... More
